(Q34338647)

1 August 2017

title

A review of current evidence for vilazodone in major depressive disorder (English)

1 reference

1 August 2017

Sheng-Min Wang

1

1 reference

1 August 2017

Changsu Han

2

1 reference

1 August 2017

Soo-Jung Lee

3

1 reference

1 August 2017

Ashwin A Patkar

4

1 reference

1 August 2017

Prakash S Masand

5

1 reference

1 August 2017

Chi-Un Pae

6

1 reference

1 August 2017

publication date

29 May 2013

1 reference

International Journal of Psychiatry in Clinical Practice

1 August 2017

published in

1 reference

1 August 2017

volume

17

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

160-169

1 reference

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Neurobiological mechanisms involved in antidepressant therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

SSRI Antidepressant Medications: Adverse Effects and Tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Serotonin autoreceptor function and antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

The Association between Economic Status and Depressive Symptoms: An Individual and Community Level Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Central 5-HT(1A) receptors: regional distribution and functional characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13651501.2013.794245

10.3109/13651501.2013.794245

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference